Published in Neuromuscul Disord on March 21, 2010
The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One (2012) 1.16
Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J (2013) 1.11
Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet (2012) 1.11
Assessing functional performance in the mdx mouse model. J Vis Exp (2014) 0.96
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis (2010) 0.89
Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation. Sci Rep (2014) 0.86
Age-related T2 changes in hindlimb muscles of mdx mice. Muscle Nerve (2015) 0.83
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor. Mol Ther Nucleic Acids (2014) 0.79
Disease course in mdx:utrophin+/- mice: comparison of three mouse models of Duchenne muscular dystrophy. Physiol Rep (2015) 0.78
Decreased sensory responses in osteocalcin null mutant mice imply neuropeptide function. Cell Mol Neurobiol (2012) 0.76
New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. FASEB J (2016) 0.75
Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F. PLoS One (2017) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29
Calling on a million minds for community annotation in WikiProteins. Genome Biol (2008) 7.11
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91
Biobanking for Europe. Brief Bioinform (2007) 2.76
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat (2009) 2.67
Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension (2006) 2.39
Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res (2012) 2.15
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
PASSion: a pattern growth algorithm-based pipeline for splice junction detection in paired-end RNA-Seq data. Bioinformatics (2012) 1.95
T-box transcription factor TBX3 reprogrammes mature cardiac myocytes into pacemaker-like cells. Cardiovasc Res (2012) 1.91
In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med (2009) 1.66
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
Comprehensive catalog of European biobanks. Nat Biotechnol (2011) 1.64
Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol (2015) 1.58
Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther (2008) 1.48
Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther (2004) 1.46
Genetic variation in T-box binding element functionally affects SCN5A/SCN10A enhancer. J Clin Invest (2012) 1.43
New methods for next generation sequencing based microRNA expression profiling. BMC Genomics (2010) 1.38
Phage display screening without repetitious selection rounds. Anal Biochem (2011) 1.36
Can subtle changes in gene expression be consistently detected with different microarray platforms? BMC Genomics (2008) 1.36
Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther (2010) 1.32
CORE_TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformatics (2008) 1.31
The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat (2015) 1.26
Splice modulating therapies for human disease. Cell (2012) 1.26
Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res (2010) 1.25
Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res (2012) 1.23
Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA. BMC Genomics (2012) 1.18
Gene expression profiling of the forming atrioventricular node using a novel tbx3-based node-specific transgenic reporter. Circ Res (2009) 1.18
Integrated analysis of microRNA and mRNA expression: adding biological significance to microRNA target predictions. Nucleic Acids Res (2013) 1.18
Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain (2011) 1.17
Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther (2013) 1.16
The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One (2012) 1.16
The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther (2008) 1.15
Novel protein-protein interactions inferred from literature context. PLoS One (2009) 1.13
Tissue-specific transcript annotation and expression profiling with complementary next-generation sequencing technologies. Nucleic Acids Res (2010) 1.13
Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J (2013) 1.11
Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet (2010) 1.10
Identification and characterization of the interaction between tuberin and 14-3-3zeta. J Biol Chem (2002) 1.09
The Pathogenesis and Therapy of Muscular Dystrophies. Annu Rev Genomics Hum Genet (2015) 1.08
Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One (2011) 1.08
Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Cancer Res (2010) 1.08
Exploring the transcriptome of ciliated cells using in silico dissection of human tissues. PLoS One (2012) 1.06
Striosomes and mood dysfunction in Huntington's disease. Brain (2006) 1.02
Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest (2010) 1.01
Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One (2010) 1.00
Serum protein profiling in mice: identification of Factor XIIIa as a potential biomarker for muscular dystrophy. Proteomics (2008) 1.00
Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. Oligonucleotides (2010) 1.00
Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul Disord (2012) 0.99
Large-scale gene expression analysis of human skeletal myoblast differentiation. Neuromuscul Disord (2004) 0.98
Microarray retriever: a web-based tool for searching and large scale retrieval of public microarray data. Nucleic Acids Res (2008) 0.96
Literature-aided interpretation of gene expression data with the weighted global test. Brief Bioinform (2010) 0.96
Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Proteomics Clin Appl (2014) 0.96
Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease. BMC Mol Biol (2008) 0.95
Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev (2013) 0.95
Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet (2008) 0.95
Tbx2 and Tbx3 induce atrioventricular myocardial development and endocardial cushion formation. Cell Mol Life Sci (2011) 0.95
Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet (2013) 0.93
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics (2011) 0.92
Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational. PLoS Curr (2013) 0.92
Literature-aided meta-analysis of microarray data: a compendium study on muscle development and disease. BMC Bioinformatics (2008) 0.91
Gene expression variation between mouse inbred strains. BMC Genomics (2004) 0.91
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells. J Immunol (2012) 0.91
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids (2013) 0.91
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis (2010) 0.89
A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging. Aging (Albany NY) (2013) 0.89
Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet (2010) 0.89
Aging as accelerated accumulation of somatic variants: whole-genome sequencing of centenarian and middle-aged monozygotic twin pairs. Twin Res Hum Genet (2013) 0.89
Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice. PLoS Curr (2013) 0.88
In silico discovery and experimental validation of new protein-protein interactions. Proteomics (2011) 0.88
Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol (2012) 0.88
Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci (2009) 0.87
DMD transcript imbalance determines dystrophin levels. FASEB J (2013) 0.87
LPAR1 and ITGA4 regulate peripheral blood monocyte counts. Hum Mutat (2011) 0.87
Determining the quality and complexity of next-generation sequencing data without a reference genome. Genome Biol (2014) 0.86
Interspecies translation of disease networks increases robustness and predictive accuracy. PLoS Comput Biol (2011) 0.86
Cell-type specific regulation of myostatin signaling. FASEB J (2011) 0.86
Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials. Neuromuscul Disord (2010) 0.86
DeepSAGE reveals genetic variants associated with alternative polyadenylation and expression of coding and non-coding transcripts. PLoS Genet (2013) 0.86
Generic information can retrieve known biological associations: implications for biomedical knowledge discovery. PLoS One (2013) 0.85
The identification of informative genes from multiple datasets with increasing complexity. BMC Bioinformatics (2010) 0.85
Gene expression profiling highlights defective myogenesis in DMD patients and a possible role for bone morphogenetic protein 4. Neurobiol Dis (2006) 0.85
Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics (2006) 0.84